Chronic Nicotine Restores Normal A - PowerPoint PPT Presentation

1 / 15
About This Presentation
Title:

Chronic Nicotine Restores Normal A

Description:

Chronic Nicotine Restores Normal A Levels and Prevents Short-term Memory and E-LTP Impairment in A Rat Model of Alzheimer s Disease Marisa Srivareerat, Trinh T ... – PowerPoint PPT presentation

Number of Views:58
Avg rating:3.0/5.0
Slides: 16
Provided by: Kimb114
Category:

less

Transcript and Presenter's Notes

Title: Chronic Nicotine Restores Normal A


1
Chronic Nicotine Restores Normal Aß Levels and
Prevents Short-term Memory and E-LTP Impairment
in Aß Rat Model of Alzheimers Disease
  • Marisa Srivareerat, Trinh T. Tran, Samina Salim,
    Abdulaziz M. Aleisa, Karim A. Alkadhi
  • University of Houston, College of Pharmacy
  • King Saud University, College of Pharmacy
  • Neurobiology of Aging 32 (2011) 834-844

Kimberly Dunbar, PA-S2 January 2012
2
Overview
  • Alzheimers disease is a progressive
    neurodegenerative disorder characterized by
    accumulation of ß-amyloid peptide, progressive
    cholinergic dysfunction, neurofibrillary tangles,
    and apoptosis in areas of the brain responsible
    for learning and memory

3
Overview
  • Excess accumulation of Aß peptide impairs
    nicotinic acetylcholine receptor (nAChR) function
    by a mechanism thought to involve a7- and
    a4ß2-nAChR blockade

4
Terms
  • BACE1 beta-site amyloid precursor protein
    cleaving enzyme 1
  • Enzyme that cleaves amyloid precursor protein to
    make Aß
  • BDNF brain-derived neurotropic factor
  • Protein that acts on certain neurons in the CNS
    and PNS to support survival of existing neurons
    and encourage growth of new neurons and synapses

5
Objective
  • To evaluate the effects of nicotine on Aß induced
    cognitive impairments of learning and short-term
    memory using various experimental approaches

6
Design
  • Rats were continuously infused with Aß peptides
    while the control groups were infused with
    inactive reverse peptide for 2 weeks
  • 4 groups
  • Nicotine
  • Nicotine/Aß
  • Control
  • Nicotine groups were treated with nicotine
    infusions twice daily for 6 weeks, prior to and
    during Aß infusion
  • Control groups received similar injections of
    normal saline

7
Inclusion Criteria
  • Adult male Wistar rats
  • Aged 49-52 days
  • 200-225 g at beginning of the experiment

8
Evaluation
  • RAWM radial arm water maze
  • In vivo electrophysiological recordings of
    early-phase long-term potentiation
  • Immunoblot assay to measure levels of BACE1,
    nAChR, and BDNF

9
Behavioral Results
  • Nicotine/Aß rats required significantly fewer
    days to meet criterion (6.360.43) than the
    compared to Aß rats (7.730.69) in the learning
    phase
  • Chronic nicotine treatment prevented an increase
    in short-term memory DTC in nicotine/Aß rats
    (5.640.41) compared to Aß rats (9.270.97)
  • Nicotine did not have any statistical
    significance in normal rats

10
Electrophysiological Results
Control Nicotine Aß Nicotine/Aß
fEPSP slope (mV/ms) 1.380.07 1.330.10 0.930.11 1.450.08
5 min post-HFS ( of baseline) 162.785.0 180.407.28 133.485.50 160.789.39
1 hr post-HFS ( of baseline) 161.484.62 163.096.35 Significantly different 150.655.25
11
Immunoblot Results
Immunoreactivity Control Nicotine Aß Nicotine/Aß
BACE1 (ratio to control) - 1.110.07 1.550.10 1.180.11
Aß1-40 (ratio to control) - 0.990.05 1.530.06 1.150.09
BDNF (ratio to control) - ?53 ?19 ?31
Immunoreactivity (ratio to control) a7-nAChR a4-nAChR ß2-nAChR
Aß ?39 ?31 ?16
Nicotine/Aß ?72 ?68 ?42
12
Conclusions
  • Cell protection against Aß toxicity can be
    achieved with chronic nicotine treatment by
    upregulation of nAChRs, activation of nAChRs to
    mediate nicotine protection against Ca2
    -dependent excitotoxicity, and inhibition of
    ß-amyloidosis, possibly due to upregulation of
    BDNF.
  • A protective effect against Aß-enhanced
    neurotoxicty can be achieved with nicotinic
    receptor stimulation and may prevent cognitive
    impairment associated with Alzheimers disease.

13
Comments
  • Misrepresented population only used male rats
  • Sample size was never mentioned
  • No value given for 1hr post-HFS for Aß
  • SEM (standard error of the mean) used instead of
    SD (standard deviation)

14
Level of Evidence
15
References
  • De Fer, Thomas M., Brisco, Meredith A., Mullur,
    Rashmi S. The Washington Manual of Outpatient
    Internal Medicine. Philadelphia, PA Lippincott
    Williams Wilkins 2010.
  • Nagele, P. Misuse of standard error of the mean
    when reporting variability of a sample A
    critical evaluation of four anaesthesia journals.
    British Journal of Anaesthesia. 200390(4)
    514-516. doi 10.1093/bja/aeg087.
  • Srivareerat M, Tran T, Salim S, et al. Chronic
    nicotine restores normal Aß levels and prevents
    short-term memory and E-LTP impairment in Aß rat
    model of Alzheimers disease. Neurobiology of
    Aging. 2011 32 834-844.
  • Wikipedia contributors. Beta-secretase 1.
    Wikipedia, The Free Encyclopedia. June 22, 2011,
    2147 UTC. Available at http//en.wikipedia.org/w
    /index.php?titleBeta-secretase_1oldid435709526.
    Accessed January 23, 2012.
  • Wikipedia contributors. Brain-derived
    neurotrophic factor. Wikipedia, The Free
    Encyclopedia. January 16, 2012, 2248 UTC.
    Available athttp//en.wikipedia.org/w/index.php?t
    itleBrain-derived_neurotrophic_factoroldid47176
    4562. Accessed January 23, 2012.
Write a Comment
User Comments (0)
About PowerShow.com